Terapia biológica: sobrevida y seguridad en padecimientos reumáticos. Resultados del Registro Nacional Biobadamex 1.0

Gabriel, 2009, Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases, Arthritis Res Ther, 19, 229, 10.1186/ar2669 Peláez-Ballestas, 2011, Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology, J Rheumatol Suppl, 86, 3, 10.3899/jrheum.100951 Mould, 2008, A multicenter study to assess the cost of rheumatoid Arthritis (RA), ankylosing spondylitis (AS), and gout, Gaceta Médica de México, 144, 225 Saag, 2008, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis and Rheum, 59, 762, 10.1002/art.23721 Goycochea-Robles, 2007, Prescription rheumatology practices among Mexican specialists, Arch Med Res, 38, 354, 10.1016/j.arcmed.2006.11.008 Smolen, 2010, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, 69, 946, 10.1136/ard.2009.126532 Chen, 2006, A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults, and an economic evaluation of their cost-effectiveness, Health Technology Assessment, 10 Curtis, 2011, Use of biologics in rheumatoid arthritis: current and emerging paradigms of care, Clin Ther, 33, 679, 10.1016/j.clinthera.2011.05.044 Maradit-Kremers, 2009, Methods to analyse real-world databases and registries Bull of the NYU, Hosp Joint Dis, 67, 193 Curtis, 2010, A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis, Semin Arthritis Rheum, 40, 2, 10.1016/j.semarthrit.2010.03.003 Pérez-Zafrilla, 2008, Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy, Reumatol Clin, 4, 90, 10.1016/S1699-258X(08)71810-2 Carmona, 2009, Actualizacion de Biobadaser, Reumatol Clin, 5, 66, 10.1016/j.reuma.2008.11.007 Ventura, 2009, Registro de acontecimientos adversos con el uso de terapia biológica en enfermedades reumáticas en México: Biobadamex, informe preliminar (C099), Revista Reumatología Clínica, 5, 66 Lunt, 2010, No evidence of association between Anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, Arthritis & Rheum, 62, 3145, 10.1002/art.27660 Carmona, 2006, Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER, Arthritis Res Ther, 8R72 Marchesoni, 2009, TNF-Alfa Antagonist survival rate in a cohort of rheumatoid arthritis patients, observed under conditions of standard clinical practice, Ann N Y Acad Sci, 1173, 837, 10.1111/j.1749-6632.2009.04621.x Pérez-Sola, 2011, Infections in patients treated with tumor necrosis factor antagonists, incidence, etiology and mortality in the Biobadaser group, Med Clin (Barc), 137, 533, 10.1016/j.medcli.2010.11.032 Singh, 2011, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Chocrane Database Syst Rev, 16, CD008794 Titton, 2011, Brazilian Biologic Registry: BiobadaBrasil implentation process and prleiminary results, Rev Bras Reumatol, 51, 145, 10.1590/S0482-50042011000200005 Lacaille, 2008, Nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis, Arthritis Rheum, 59, 1074, 10.1002/art.23913 Gomez-Reino, 2003, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk, Arthritis Rheum, 48, 2122, 10.1002/art.11137 Gomez-Reino, 2007, Risk of tuberculosis in patients treated with tumor necrosis factor antagonist due to incomplete prevention of reactivation of latent infection, Arthritis and Rheum, 57, 756, 10.1002/art.22768 Carmona, 2007, All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor, Ann Rheum Dis, 66, 880, 10.1136/ard.2006.067660 Adebajo, 2005, Biologics agents and their use in resource poor countries. Editorial, J Rheumatol, 32, 7 Katz, 2009, Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists, Arthritis Rheum, 61, 593, 10.1002/art.24511